Ethiopia IVF Clinic Economics: Fertility Treatment Cost Data
- The Consultation That Reveals the Data Vacuum
- Per-Cycle Cost Anatomy From Stimulation to Transfer
- The Medication Import Dependency and Forex Exposure
- Success Rate Measurement and the Outcome Reporting Gap
- Patient Demographics and the Affordability Ceiling
- The Investment Case and the Missing Market Intelligence
In a consultation room on the fourth floor of a medical building in Bole, Addis Ababa, Dr. Selam Teferi explains to a couple that their IVF cycle will cost ETB 320,000 and carry a 32% probability of resulting in a live birth, while acknowledging that she cannot tell them how her success rates compare to other Ethiopian clinics because no national registry or benchmarking framework exists. Ethiopia's assisted reproduction sector operates in a data vacuum where clinic-level outcomes, cost structures, and patient demographics remain uncollected, making it impossible for patients to make informed choices or for investors to size the market accurately. AskBiz helps fertility clinics like Dr. Selam's build the per-cycle cost tracking and outcome documentation that the sector needs to move from opaque pricing to evidence-based reproductive medicine.
- The Consultation That Reveals the Data Vacuum
- Per-Cycle Cost Anatomy From Stimulation to Transfer
- The Medication Import Dependency and Forex Exposure
- Success Rate Measurement and the Outcome Reporting Gap
- Patient Demographics and the Affordability Ceiling
The Consultation That Reveals the Data Vacuum#
The fluorescent lights hum in Dr. Selam Teferi's consultation room in Bole, Addis Ababa, where she has just finished reviewing a couple's diagnostic workup. The wife, 34, has bilateral tubal occlusion confirmed by hysterosalpingography. The husband's semen analysis shows moderate oligoasthenozoospermia. Their path to parenthood runs through in vitro fertilisation. Dr. Selam has delivered this consultation several hundred times over eight years of fertility practice, and she knows exactly what comes next. The couple will ask three questions: how much does IVF cost, what are the chances it will work, and how does this clinic compare to others. She can answer the first question precisely. A standard IVF cycle at her clinic, Hanna Fertility Centre, costs ETB 280,000-ETB 350,000 depending on the stimulation protocol and whether intracytoplasmic sperm injection is required. With ICSI, which this couple will need, the cost is ETB 320,000-ETB 380,000. She can partially answer the second question. Her clinic's internal data shows a clinical pregnancy rate of 38% per embryo transfer for women under 35 and 28% for women aged 35-39, with live birth rates approximately 6-8 percentage points lower after accounting for miscarriage. The third question she cannot answer honestly. Ethiopia has no national assisted reproduction registry. No regulatory body collects or publishes cycle-level outcome data from fertility clinics. There is no Ethiopian equivalent of the HFEA in the United Kingdom or the CDC ART surveillance system in the United States. Dr. Selam does not know whether her 38% clinical pregnancy rate for under-35 patients is above average, below average, or typical for Ethiopian IVF clinics. She does not know how many IVF cycles are performed annually in Ethiopia, how many clinics offer the service, or what the aggregate national success rates are. This data vacuum has consequences that extend far beyond patient counselling.
Per-Cycle Cost Anatomy From Stimulation to Transfer#
The cost of an IVF cycle at Hanna Fertility Centre breaks down into five distinct phases, each with its own cost drivers and variability. The initial consultation and diagnostic phase costs ETB 15,000-ETB 25,000, covering the first consultation, baseline ultrasound, hormonal panel including AMH, FSH, LH, oestradiol, and thyroid function, semen analysis, and infectious disease screening for both partners. This phase generates approximately 5% of total cycle revenue but serves as the clinical gateway that determines whether IVF is indicated and which protocol to recommend. The ovarian stimulation phase is the largest variable cost component. Gonadotropin medications, primarily recombinant FSH and hMG, cost ETB 80,000-ETB 140,000 per cycle depending on the dose required. Women with lower ovarian reserve require higher doses and longer stimulation periods, pushing medication costs toward the upper range. Dr. Selam sources gonadotropins from two importers in Addis Ababa, paying ETB 3,500-ETB 4,800 per 75 IU vial of recombinant FSH. A standard antagonist protocol for a normal responder requires 1,500-2,500 IU total, consuming 20-33 vials. Monitoring during stimulation adds ETB 12,000-ETB 18,000 in serial ultrasound scans and blood hormone levels over 10-14 days. The oocyte retrieval procedure costs ETB 35,000-ETB 45,000, covering the operating theatre, anaesthesia, ultrasound-guided aspiration, and embryology laboratory processing. The laboratory phase, encompassing oocyte identification, sperm preparation, fertilisation by conventional IVF or ICSI, and embryo culture for 3-5 days, costs ETB 40,000-ETB 60,000. ICSI adds ETB 15,000-ETB 20,000 to the laboratory cost. The embryo transfer procedure itself costs ETB 25,000-ETB 30,000, and luteal phase support medications add ETB 8,000-ETB 12,000. The total cycle cost of ETB 280,000-ETB 380,000 makes IVF accessible only to upper-income Ethiopian families or those with access to savings or family financial support.
The Medication Import Dependency and Forex Exposure#
Fertility medications represent 35-45% of total IVF cycle cost, and virtually every medication used in assisted reproduction in Ethiopia is imported. Gonadotropins come from Merck, Ferring, and generic manufacturers in India. GnRH antagonists for ovulation suppression are imported from European and Indian sources. Progesterone for luteal support is imported. Even basic laboratory consumables including culture media, ICSI needles, and embryo transfer catheters are entirely imported. Dr. Selam's medication procurement is channelled through two EFDA-licensed pharmaceutical importers. Her purchasing power is limited by the small scale of her operation. Hanna Fertility Centre performs 12-16 IVF cycles per month, consuming approximately ETB 1.2-ETB 1.8 million in medications monthly. This volume does not command significant bulk pricing from importers, unlike larger hospitals that purchase across multiple specialties. The foreign exchange situation in Ethiopia creates a structural cost risk that Dr. Selam cannot hedge. Medication prices from importers are effectively pegged to USD through informal indexing, even though transactions are denominated in ETB. When the birr depreciates against the dollar, importer prices adjust within 2-4 weeks. The birr has depreciated from approximately ETB 55 per USD in early 2023 to ETB 130-135 per USD in mid-2026 following the forex liberalisation measures. This depreciation has more than doubled the ETB cost of imported medications. A vial of recombinant FSH that cost ETB 1,800 in 2023 now costs ETB 3,500-ETB 4,800. Dr. Selam has passed approximately 70% of this cost increase to patients, with her cycle prices rising from ETB 180,000-ETB 220,000 in 2023 to ETB 280,000-ETB 380,000 currently. The remaining 30% has compressed her margins. AskBiz tracks medication costs per cycle at the vial level, correlating procurement costs with forex movements and generating alerts when medication price increases exceed thresholds that require patient pricing adjustments.
Data-backed guides on AI, eCommerce, and SME strategy — straight to your inbox.
Success Rate Measurement and the Outcome Reporting Gap#
Dr. Selam's internal outcome tracking covers every cycle performed at Hanna Fertility Centre since its opening in 2021. Her database records 847 completed stimulation cycles, 792 oocyte retrievals, 724 fresh embryo transfers, and 186 frozen embryo transfers over four and a half years. The clinical pregnancy rate per embryo transfer is 35.2% overall, stratified as 38.4% for women under 35, 32.1% for women aged 35-37, 24.8% for women aged 38-40, and 16.3% for women over 40. The live birth rate per transfer is 29.8% overall, 33.1% for under-35, 27.4% for 35-37, 19.2% for 38-40, and 11.7% for over-40. These numbers are clinically meaningful but operationally isolated. Dr. Selam has no external benchmark to evaluate them against. Ethiopia has an estimated 8-12 clinics offering IVF services, concentrated in Addis Ababa with one or two in regional cities. None publish outcome data. The Ethiopian Medical Association does not collect or report assisted reproduction statistics. The EFDA regulates medication and device imports but does not mandate clinical outcome reporting from fertility clinics. The absence of a national registry creates multiple problems. Patients cannot comparison-shop based on outcome data. Clinics have no incentive to improve because there is no competitive transparency. Investors cannot assess clinical quality when evaluating fertility clinic investments. Health insurers, if they were to consider covering IVF, have no actuarial basis for estimating per-cycle costs or expected utilisation. The data gap also enables clinics with lower success rates to market aggressively without accountability, while clinics like Dr. Selam's that invest in embryology laboratory quality and clinical protocols cannot demonstrate their relative performance advantage. AskBiz provides the cycle-level tracking infrastructure that would underpin a future national registry, recording stimulation parameters, oocyte yields, fertilisation rates, embryo quality grades, transfer outcomes, and pregnancy follow-up in a structured format that enables both clinic-level quality improvement and cross-clinic benchmarking.
Patient Demographics and the Affordability Ceiling#
The patient population at Hanna Fertility Centre reflects the extreme affordability constraints of IVF in Ethiopia. At ETB 280,000-ETB 380,000 per cycle, IVF costs roughly 8-12 times the average monthly income of a mid-level professional in Addis Ababa. The majority of Dr. Selam's patients fall into three demographic categories. The first is dual-income professional couples aged 30-40 where both partners work in sectors such as banking, NGOs, government ministries, or private enterprise, with combined monthly incomes of ETB 40,000-ETB 80,000. These couples typically save for 6-18 months before starting IVF. The second category is diaspora-connected families where a relative abroad provides financial support. Dr. Selam estimates that 25-30% of her patients receive full or partial funding from family members in the United States, Europe, or the Middle East. The third category is older couples, typically with the woman aged 38-43, who have exhausted other treatment options and are making a final attempt at biological parenthood, often funded by liquidating savings or borrowing from family. No Ethiopian health insurance plan covers IVF. The out-of-pocket nature of payment means that most patients can afford only one cycle. Dr. Selam's data shows that 68% of patients complete exactly one fresh cycle. Only 22% proceed to a second cycle, and 10% attempt three or more cycles. The cumulative live birth rate across three cycles is significantly higher than the per-cycle rate, reaching approximately 55-60% for women under 35. But the affordability ceiling means most patients never access the statistical benefit of multiple attempts. AskBiz helps Dr. Selam present patients with transparent cost projections for multi-cycle treatment plans, including the option of batch stimulation with embryo freezing that can reduce the per-attempt cost of subsequent frozen embryo transfers to ETB 80,000-ETB 120,000 versus ETB 280,000 or more for a full fresh cycle.
The Investment Case and the Missing Market Intelligence#
Sub-Saharan Africa's fertility services market is attracting increasing investor attention, with notable transactions in South Africa and Nigeria's IVF sectors in recent years. Ethiopia, with a population of 126 million, an estimated infertility prevalence of 15-20% among couples of reproductive age, and a total installed IVF capacity serving fewer than 2,000 cycles annually, presents what appears to be a large and underserved market. However, the investment thesis collapses quickly when due diligence reveals the extent of the data gap. An investor conducting diligence on Hanna Fertility Centre or any Ethiopian IVF clinic would need answers to questions that the market currently cannot provide. What is the total addressable market in terms of couples who are both clinically indicated for IVF and able to pay? No survey data exists. What is the competitive landscape in terms of clinic capacity, pricing, and outcomes? No registry or directory provides this information. What is the patient acquisition cost and what referral channels are most effective? No marketing analytics exist at the sector level. What regulatory changes are likely, particularly regarding insurance mandates for fertility coverage? No policy roadmap has been published. Dr. Selam's operation at Hanna Fertility Centre generates ETB 4.5-ETB 6.2 million in monthly revenue from 12-16 IVF cycles plus ancillary services including IUI, fertility assessments, and hormonal treatments. Her net margin after all costs including physician salaries, laboratory operations, rent at ETB 120,000 per month for her Bole premises, and medication procurement sits at 15-22% depending on cycle volume and medication cost fluctuations. These are attractive unit economics, but they describe one clinic in one city. AskBiz is the tool that bridges the gap between single-clinic operations data and sector-level market intelligence. By providing fertility clinics with standardised cycle tracking, cost accounting, and outcome reporting, the platform creates the possibility of aggregated, anonymised benchmarks that investors, regulators, and insurance designers need to engage seriously with Ethiopia's assisted reproduction sector. For Dr. Selam, AskBiz is a practice management tool. For the sector, it is the missing measurement infrastructure.
Our team combines expertise in data analytics, SME strategy, and AI tools to produce practical guides that help founders and operators make better business decisions.
Ready to make smarter decisions?
AskBiz turns your business data into actionable intelligence — no spreadsheets, no consultants.
Start free — no credit card required →